ARTICLE
7 February 2022

COVID-19 Key EU Developments, Policy & Regulatory Update No. 74

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
This regular update (no. 74 | 24 January 2022) covers key regulatory EU developments related to the evolving COVID-19 situation (Antitrust & State Aid; Trade/Export Controls;
European Union Coronavirus (COVID-19)
Kaarli H. Eichhorn’s articles from Jones Day are most popular:
  • with Inhouse Counsel
  • in Asia

This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.

LATEST KEY DEVELOPMENTS

Competition & State Aid

  • European Commission approves new and amended Member State measures to support the economy

Trade / Export Controls

  • No noteworthy developments for this issue

Medicines and Medical Devices

  • EMA publishes COVID-19 vaccines safety update
  • European Parliament endorses agreement with Council on reinforced role for EMA crisis preparedness and management for medicinal products and medicinal devices
  • Ministers of Health of EU Member States and EU Commissioner for Health and Food Safety discuss Resilience of Health Systems to Support Cooperation on a European Scale

Cybersecurity, Privacy & Data Protection

  • Council of the European Union adopts Recommendation on a coordinated approach to facilitate safe free movement during COVID-19 pandemic
  • ENISA publishes reports on security of digital identification

To view the full article please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More